Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
Published Date: 02 Mar 2023
The legal team said the jury's decision could make medics think twice before allowing the injured to return to the field.
Read Full NewsFrontlines with Frontera, a podcast hosted by neurointensivist Jennifer Frontera, MD, brings you an exclusive interview with Sahar Zafar, MD, MBBS. [LISTEN TIME: 30 minutes]
Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending December 19, 2025.
GLP-1 research in neurology is on the rise, with several pivotal studies lending insights into their role.
Fear of Movement, Central Sensitization May Worsen Outcomes in Gout
FDA Extends PDUFA Date for Reproxalap in Dry Eye Disease to March 2026
FDA Accepts, Grants Priority Review to Veligrotug BLA for Thyroid Eye Disease
Weight-Loss Interventions Improve Psoriasis Severity, Quality of Life
1.
Since 2000, the outlook for multiple myeloma has improved.
2.
Ineffective medication can remove the "worst fear" of schizophrenia.
3.
BMTs that are "half-matched" are effective in treating severe sickle cell disease.
4.
Loncastuximab-Rituximab Boosts Response Rates in R/R Follicular Lymphoma
5.
According to a study, white Americans are overdiagnosing melanoma at an alarming rate.
1.
Gene Signatures and Their Implications in Oncology: Decoding the Blueprint for Personalized Cancer Treatment
2.
Transplant Oncology and Anti-Cancer Immunosuppressants: The Evolution of a Paradigm in Cancer Care
3.
Unlocking the Potential of Ferrotonia: A New Way to Harness Magnetic Energy
4.
Unlocking the Potential of SCD: A Comprehensive Guide to Diagnosis and Treatment
5.
Apheresis vs. IVMP in Cancer Treatment: A Tale of Two Titans
1.
International Lung Cancer Congress®
2.
Future NRG Oncology Meeting
3.
Genito-Urinary Oncology Summit 2026
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Current Scenario of Blood Cancer- Genomic Testing & Advancement in Diagnosis and Treatment
2.
Should We Use DARA Up Front As First-Line Therapy in MM? - Part II
3.
Efficient Management of First line ALK-rearranged NSCLC - Part V
4.
Updates on Standard V/S High Risk Myeloma Treatment
5.
The Evolving Landscape of First-Line Treatment for Urothelial Carcinoma
Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
© Copyright 2025 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
To get started please enter your email ID
Join to enhance your clinical skills and gain specialized in-depth medical knowledge